Roche’s Vabysmo secures a new FDA nod for retinal vein occlusion treatment, intensifying the competition with Regeneron and Bayer’s Eylea in the eye medication market. This approval for Vabysmo in RVO adds another shared medical indication for the competing eye medications. Vabysmo’s successful FDA approval for RVO follows its earlier nods from the FDA for treating wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
Collectively, these three retinal conditions impact approximately 3 million individuals in the United States and stand as primary contributors to vision impairment. As per DelveInsight analysis, in the year 2021, the total retin...
